

## Summit Program

— PERSONALIZED THERAPY FOR OPTIMAL CARE —

### DAY 1 | SATURDAY 4 MAY

#### SESSION I :

#### GENERAL SESSION (8:20 AM - 11:10 AM)

Chairpersons: Toh Han Chong, Singapore | Chee Cheng Ean, Singapore

8:20 AM - 8:30 AM

#### Opening Remarks

Toh Han Chong, Singapore

8:30 AM - 9:00 AM

#### Keynote Lecture 1

**The evolving role of personalized GI Cancer care: Past, Present & Back to the Future**

Axel Grothey, USA

9:00 AM - 9:30 AM

#### An aerial view of 2018 in GI Cancers : What did we learn?

Shaheenah Dawood, UAE

9:30 AM - 10:00 AM

#### Keynote Lecture 2

**The best treatment strategy for advanced Gastric Cancer in modern era of biomarkers**

Sun Young Rha, South Korea

10:00 AM - 10:30 AM

#### Coffee Break

10:30 AM - 11:10 AM

#### Multidisciplinary Tumour Board I: Molecular tumour board for Upper GI Cancers

Moderator: Axel Grothey, USA

Panelists: Sun Young Rha, South Korea | Yong Wei Peng, Singapore | Jimmy So, Singapore | Azrif Muhammad, Malaysia | Syed Akram, Bangladesh | Aru Sudoyo, Indonesia | Jian Xiao, China | Anita Ramesh, India

#### SESSION II:

#### IMMUNOTHERAPY IN GI CANCERS (11:10 AM - 12:45 PM)

Chairpersons: Toh Han Chong, Singapore | Ian Chau, UK

11:10 AM - 11:15 AM

#### Five important questions we want to answer today!

Toh Han Chong, Singapore

11:15 AM - 11:35 AM

#### Immunotherapeutics in Gastric Cancer

Keun-Wook Lee, South Korea

*Session Supported by BMS*

11:35 AM - 11:55 AM

#### Immunotherapeutics in Colorectal Cancer

Shaheenah Dawood, UAE

11:55 AM - 12:15 PM

#### Management of Immuno-Oncology drug related toxicities

Ian Chau, UK

12:15 PM - 12:45 PM

#### Multidisciplinary Tumour Board II: Using immune checkpoint inhibitors: Real world cases

Moderator: Sun Young Rha, South Korea

Panelists: Sung Bae Kim, South Korea | Axel Grothey, USA | Matthew Ng, Singapore | Aru Sudoyo, Indonesia

Organised by

12:45 PM – 1:30 PM

**LUNCH & BAYER SATELLITE SYMPOSIUM**

**Patients First: Advancing the standard of care for patients**

Chairperson: Kong Hwai Loong, Singapore

**Boosting treatment outcomes in solid tumours with MKIs**

Axel Grothey, USA

**The Asian experience: Strategies to optimise systemic treatments to prolong OS in HCC**

Sadahisa Ogasawara, Japan

**SESSION III:**

**PERSONALIZING THERAPY FOR HCC (1:30 PM - 3:15 PM)**

Chairpersons: Pierce Chow, Singapore | Choo Su Pin, Singapore

1:30 PM – 1:45 PM

**Portending the future: How will a positive 1st line trial with check-point inhibitors in HCC change the treatment paradigm in HCC**

Thomas Yau, HK

1:45 PM – 2:00 PM

**Portending the future: If there were a negative 1st line trial with check-point inhibitors in HCC, what would subsequent clinical trials be like?**

Stephen Chan, HK

2:00 PM – 2:15 PM

**Emerging paradigms in the management of locally advanced HCC**

Jens Ricke, Germany

2:15 PM – 2:30 PM

**The potential for cure with resection in HCC – A metro-ticket approach**

Pierce Chow, Singapore

2:30 PM – 3:00 PM

**Multidisciplinary Tumour Board III: Real World Management of HCC**

Moderator: Pierce Chow, Singapore

Panelists: Choo Su Pin, Singapore | David Ng, Singapore | Apoorva Gogna, Singapore |

Kiat Ho Tony Lim, Singapore | Jens Ricke, Germany | Thomas Yau, HK | Stephen Chan, HK |

Alfred Kow, Singapore

3:00 PM – 3:15 PM

**Systemic therapy in the management of advanced HCC**

Stephen Chan, HK

*Session is supported by IPSEN*

3:15 PM – 4:00 PM

**COFFEE & MSD SATELLITE SYMPOSIUM**

**Advances in the management of Esophageal Cancer**

Sung Bae Kim, South Korea

Organised by

**DAY 2 | SUNDAY 5 MAY**

**SESSION IV: CONTROVERSIES IN THE MANAGEMENT OF PANCREATIC CANCER  
(8:30 AM - 9:30 AM)**

Chairpersons: Shailesh Shrikande, India

**8:30 AM - 9:00 AM**

**Debate: All patients of resectable pancreas cancer should receive neoadjuvant chemotherapy first!**

YES: Goro Honda, Japan

NO : Shailesh V. Shrikhande, India

**9:00 AM - 9:30 AM**

**Pancreatic Tumour Board- Real world management across the broad, wide, diverse lands of Asia**

Moderator : Bhawna Sirohi, India

Panelists : Azrif Muhammad, Malaysia | Syed Akram, Bangladesh | Jian Xiao, China | Goro Honda, Japan | Shailesh Shrikande, India | Brian Goh, Singapore | Damien Tan, Singapore | Anita Ramesh, India

**SESSION V: COLORECTAL CANCER : CHALLENGING CLINICAL SCENARIOS  
(9:30 AM - 12:35 PM)**

**Challenging Scenario (1) - (9:30 AM - 10:35AM)**

Chairpersons: Iain Tan, Singapore | Aru Sudoyo, Indonesia

**9:30 AM - 10:00 AM**

**Keynote Lecture (3)**

**The molecular and immune biology of Colorectal Cancer as it relates to clinical treatments: A summary of what we have learnt in the last 2 years**

Sabine Tejpar, Belgium

**10:00 AM - 10:20 AM**

**MSI-H CRC - it's impact on adjuvant treatment decisions, and in late stage, sequencing of immunotherapy and chemotherapy and management at progression - current data - Q & A**

Kai Keen Shiu, UK

*Session is supported by BMS*

**10:20 AM - 10:35 AM**

**Case Discussion:**

Facilitated by Koo Si-Lin, Singapore

Panelists: Sabine Tejpar, Belgium | Axel Grothey, USA | Kentaro Yamazaki, Japan | Ian Chau, UK | Raghav Sundar, Singapore | Kai-Keen Shiu, UK

**10:35 AM - 10:50 AM**

**Coffee Break**

**Challenging Scenario (2) - (10:50 AM - 11:25 AM)**

Chairpersons: Clarinda Chua, Singapore | Raghav Sundar, Singapore

**10:50 AM- 11:05 AM**

**Right-sided Colon Cancer: What is the optimal treatment sequence in right sided colon cancer for (a) conversion therapy (b) high volume disease (c) intermediate volume disease**

Kentaro Yamazaki, Japan

*Session is supported by Merck*

**11:05 AM - 11:10 AM**

**Q & A**

**11:10 AM -11:25 AM**

**Case Discussion:**

Facilitated by Yong Wei Peng, Singapore

Panelists : Sabine Tejpar, Belgium | Axel Grothey, USA | Kentaro Yamazaki, Japan | Ian Chau, UK |

Chan Chung Yip, Singapore | Alfred Kow, Singapore | Tan Wah Siew, Singapore | Clarinda Chua, Singapore

**Challenging Scenario (3) - (11:25 AM - 12:00 PM)**

Chairpersons: Shaheenah Dawood, UAE | Toh Han Chong, Singapore

**11:25 AM - 11:40 AM**

**Management of synchronous Rectal Cancer in the presence of resectable distant metastases**

Chee Cheng Ean, Singapore

**11:40 AM - 11:45 AM**

**Q & A**

**11:45 AM - 12:00 PM**

**Case Discussion:**

Facilitated by Tan Wah Siew, Singapore | Iain Tan, Singapore

Panelists : Sabine Tejpar, Belgium | Axel Grothey, USA | Kentaro Yamazaki, Japan | Tan Ker Kan, Singapore |

Connie Yip, Singapore | Chee Cheng Ean, Singapore | Alfred Kow, Singapore

**Challenging Scenario (4) - (12:00 PM - 12:35 PM)**

Chairpersons: Shaheenah Dawood, UAE | Toh Han Chong, Singapore

**12:00 PM- 12:15 PM**

**Selecting antiangiogenic agents in 1st, maintenance and beyond progression in CRC: Practical Considerations**

Ian Chau, UK

*Session is Supported by Lilly Oncology*

**12:15 PM - 12:20 PM**

**Q & A**

**12:20 PM - 12:35 PM**

**Case Discussion:**

Facilitated by Ian Chau, UK | Chee Cheng Ean, Singapore

Panelists : Sabine Tejpar, Belgium | Axel Grothey, USA | Kentaro Yamazaki, Japan | Yong Wei Peng, Singapore

**CLOSING REMARKS & LUNCH**